ENTO: enterothera.com Company Value to Net Income

Symbol and logo of brand Entero Therapeutics (ENTO)

Entero Therapeutics, Inc. (ENTO) relies on a compact staff of specialized researchers motivated by stock options and operational autonomy. The business's financial stability is currently tied to external investments and test results, as the commercial launch of its products has not yet occurred. The PE ratio stands at -0.60, which is clearly demonstrated by the current share price chart for the company on the GURU.Markets platform.

ENTO Entero Therapeutics P/E Multiple (05/18/2024 - 12/01/2025)

Comprehensive metric breakdowns and analytics for Entero Therapeutics Inc. (ENTO)

- price and consensus price forecast:
Comprehensive company analysis:Entero ENTO
Finished products of Entero Therapeutics

P/E reflects the ratio of market capitalization to net income, measuring the cost of one dollar of annual earnings. The multiplier's value reacts instantaneously to changes in quarterly financial results. By analyzing the P/E history of a company, an investor assesses the extent of the premium paid for future growth. For Entero Therapeutics, Inc. (ENTO), the efficiency of laboratory robotization reduces costs, directly impacting the denominator of the formula. This optimizes the fundamental value of the business.